294 completed, 56 recruiting, 29 terminated, 29 unknown. 450 Phase 2, 64 Phase 1, 59 Phase 3.
Follow Dyssomnias: new trials by email Literature Review of Dyssomnias trials Research Report on Dyssomnias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep Ferrous Sulfate, Placebo - ADHD, Sleep Problems | Phase 1 / Phase 2 | Not yet recruiting | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | 70 | 2027-03-01 | 2026-05-04 |
| Study to Examine the Effect of Silicone Mouth Tape on Snoring and Mild Sleep Apnea. Mouth Tape - Mild Obstructive Sleep Apnea, Snoring | Phase 2 | Recruiting | Johns Hopkins University | 100 | 2027-03-01 | 2026-06-23 |
| Tolerability and Efficacy of CBD Extract for RLS Treatment BRC-002, Placecbo - Restless Leg Syndrome | Phase 2 | Not yet recruiting | University of Colorado, Denver | 60 | 2026-11-01 | 2026-10-08 |
| A Study Of Synthetic THC And Sleep Dronabinol, Placebo - Obstructive Sleep Apnea | Phase 2 / Phase 3 | Not yet recruiting | Mayo Clinic | 72 | 2026-11-01 | 2026-09-18 |
| A Trial of ALN-6457 in Adult Participants With Symptomatic Prion Disease (PrD) ALN-6457 - Prion Disease | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 60 | 2026-10-23 | 2026-09-22 |
| THC Versus THC/CBD Versus Placebo to Improve Sleep Quality for Patients With Solid Organ Cancer and Insomnia Biospecimen Collection, Placebo Administration, Single Agent Therapy - Insomnia, Malignant Solid Neoplasm | Phase 2 | Not yet recruiting | Mayo Clinic | 69 | 2026-10-01 | 2026-09-02 |
| Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness Trial Continuous Positive Airway Pressure, Tirzepatide - Sleep Apnoea, Obesity & Overweight | Phase 2 / Phase 3 | Not yet recruiting | Woolcock Institute of Medical Research | 256 | 2026-10-01 | 2026-09-29 |
| Intravenous Iron in the Management of Drug-resistant Restless Legs syndromeI Ferric Carboxymaltose Injection [Ferinject], Randomization, Questionnaire and Physical Exam - Restless Legs Syndrome (RLS) | Phase 2 | Not yet recruiting | University Hospital, Montpellier | 66 | 2026-10-01 | 2026-09-16 |
| A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder ALKS 7290 Dose, Placebo - Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Alkermes, Inc. | 180 | 2026-10-01 | 2026-10-28 |
| Deep Sleep in Older Adults SleepSpaceRx CBT-I-IoT-AI, SleepEZ CBTi, Sleep Hygiene IoT - Insomnia, Insomnia Chronic | Phase 2 | Recruiting | Proactive Life Inc | 180 | 2026-09-30 | 2026-10-20 |
| Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy), Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition, Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition - Obstructive Sleep Apnea, Sleep-disordered Breathing | Phase 1 / Phase 2 | Recruiting | Brigham and Women's Hospital | 24 | 2026-09-01 | 2026-09-21 |
| Daridorexant for People With Insomnia and Alcohol Use Disorder Study Daridorexant, Placebo, Brief Counseling - Alcohol Use Disorder, Insomnia | Phase 2 | Not yet recruiting | Sterling McPherson | 205 | 2026-09-01 | 2026-07-14 |
| The Optimal One-Month Dosing of Lemborexant for Moderate Obstructive Sleep Apnea (OSA) Patients With Low Arousal Threshold Lemborexant 5 MG [Dayvigo] Period 1, Placebo Period 1, Lemborexant 5 MG [Dayvigo] Period 2 - OSA - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Not yet recruiting | Chulalongkorn University | 36 | 2026-09-01 | 2026-07-06 |
| Understanding the Role of the Locus Coeruleus in Insomnia Dexmedetomidine, Placebo - Insomnia | Phase 2 | Recruiting | Woolcock Institute of Medical Research | 15 | 2026-08-12 | 2026-08-19 |
| Efficacy and Safety of APSTZD in the Treatment of Insomnia Disorder APSTZD 1, APSTZD 2, APSTZD 3 - Insomnia, Insomnia Chronic | Phase 2 | Recruiting | Apsen Farmaceutica S.A. | 222 | 2026-08-05 | 2026-08-21 |
| DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea. IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 125 mg acetazolamide - Obstructive Sleep Apnea (OSA) | Phase 2 | Recruiting | Incannex Healthcare Ltd | 120 | 2026-07-21 | 2026-10-13 |
| Post-Operative Steroids After Sleep Surgery 8mg dexamethasone - Obstructive Sleep Apnea | Phase 2 | Withdrawn | Medical University of South Carolina | 2026-07-01 | 2026-10-06 | |
| A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia TAK-360, Placebo - Idiopathic Hypersomnia, Narcolepsy Type 1 | Phase 2 / Phase 3 | Recruiting | Takeda | 500 | 2026-06-11 | 2026-10-27 |
| A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy) TAK-360, Placebo - Narcolepsy Type 1 | Phase 2 | Recruiting | Takeda | 92 | 2026-06-04 | 2026-06-29 |
| A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence cleminorexton, Placebo - Narcolepsy Type 1, Narcolepsy Type 2 | Phase 2 / Phase 3 | Recruiting | Centessa Pharmaceuticals (UK) Limited | 222 | 2026-05-29 | 2026-10-02 |
Showing 20 of 450. Sign in to see all of them.
Sleep Initiation and Maintenance Disorders (164) · Sleep Apnea, Obstructive (126) · Sleep Apnea Syndromes (73) · Restless Legs Syndrome (46) · Disorders of Excessive Somnolence (35) · Sleep Wake Disorders (27) · Narcolepsy (23) · Depression (17) · Idiopathic Hypersomnia (16) · Hypertension (13) · Anxiety Disorders (12) · Obesity (12) · Parasomnias (11) · Pain (10) · Sleep Deprivation (10)
Nervous System Diseases (445) · Sleep Disorders, Intrinsic (431) · Sleep Wake Disorders (423) · Mental Disorders (286) · Respiratory Tract Diseases (177) · Respiration Disorders (171) · Apnea (168) · Pathological Conditions, Signs and Symptoms (108) · Sleep Apnea Syndromes (100) · Signs and Symptoms (86) · Neurologic Manifestations (59) · Parasomnias (45) · Central Nervous System Diseases (35) · Brain Diseases (32)
Continuous Positive Airway Pressure (14) · Acetazolamide (12) · Atomoxetine Hydrochloride (12) · Cognitive Behavioral Therapy (12) · Melatonin (12) · Zolpidem (12) · Modafinil (10) · Sugars (10) · Eszopiclone (9) · lemborexant (9) · ramelteon (9) · solriamfetol (9) · suvorexant (8) · Dexmedetomidine (6) · Sodium Oxybate (6)
Brigham and Women's Hospital (27) · Takeda (12) · GlaxoSmithKline (11) · Apnimed (10) · VA Office of Research and Development (10) · Johns Hopkins University (9) · University of California, San Diego (9) · Duke University (8) · Stanford University (7) · Alkermes, Inc. (5) · Jazz Pharmaceuticals (5) · University of Michigan (5) · University of Utah (5) · American Regent, Inc. (4) · Boehringer Ingelheim (4)
United States (277) · France (28) · Canada (26) · Germany (22) · Australia (21) · Italy (18) · Spain (18) · China (12) · Japan (12) · Switzerland (10) · Belgium (9) · Netherlands (9) · United Kingdom (7) · Czechia (5) · Austria (4)
Scott A Sands, PhD (6) · Atul Malhotra, MD (3) · Bradley A Edwards, PhD (3) · Carl J Stepnowsky, PhD (3) · Brendon Yee, MBChB, FRACP, FCCP, PhD (2)
PMID 39688178, PMID 36494591, PMID 41170811, PMID 10341379, PMID 11918106, PMID 12105286, PMID 12126214, PMID 14733976, PMID 15112907, PMID 16491981, PMID 17109795, PMID 17294232, PMID 17352947, PMID 17441783, PMID 17513285, PMID 17520797, PMID 17671050, PMID 17690599, PMID 18457236, PMID 18482867, PMID 18513353, PMID 18555170, PMID 18678823, PMID 18711110, PMID 18753003, PMID 18840807, PMID 18853704, PMID 19054552, PMID 19122865, PMID 19186083, PMID 19192466, PMID 19393404, PMID 19398354, PMID 19491110, PMID 19581560, PMID 20086074, PMID 20297950, PMID 20435443, PMID 20466589, PMID 20620105, PMID 20920156, PMID 21306949, PMID 21397868, PMID 21557231, PMID 21614467, PMID 21643649, PMID 21704134, PMID 21705273, PMID 21784661, PMID 21799479
2025 (4), 2015 (3), 2009 (2), 2017 (2), K23HL151880 (2), 1IK2CX000547 (1), 2004 (1), 2005 (1), 2014 (1), 2019 (1), 2023 (1), IK2CX002363-01A1 (1), K07CA132916 (1), K23AT003678 (1), K23AT012475 (1)